Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib PK and Safety in Pediatric Severe Atopic Dermatitis
NCT03646604Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of upadacitinib in atopic dermatitis (AD) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration up to 7 days, Time to Maximum Observed Plasma Concentration up to 7 days and 3 more. Started Jan 2019; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03646604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646604.